Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.

Trial Profile

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2012

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT00496808).
    • 12 May 2009 Planned number of patients changed from 20 to 71 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top